You are here

G1 THERAPEUTICS, INC.

Company Information
Address
79 TW Alexander Dr
RESEARCH TRIANGLE PARK, NC 27709-0152
United States



Information

UEI: L72RA25Z7LK3

# of Employees: N/A


Ownership Information

HUBZone Owned: No

Socially and Economically Disadvantaged: No

Woman Owned: No



Award Charts




Award Listing

  1. Development of GZ38-1, a Novel Protectant of Chemotherapy-Induced Myelosuppressio

    Amount: $984,830.00

    DESCRIPTION provided by applicant Myelosuppression continues to represent the major dose limiting toxicity of cancer chemotherapy resulting in considerable morbidity and mortality along with frequ ...

    SBIRPhase II2014Department of Health and Human Services National Institutes of Health
  2. Development of CDK4/6 Inhibitors as Novel Renal Protectants

    Amount: $159,836.00

    DESCRIPTION (provided by applicant): Acute kidney injury (AKI) is common, expensive, and highly morbid. There are currently no therapies for AKI, and prevention and treatment represents a 6.3 billion ...

    SBIRPhase I2013Department of Health and Human Services National Institutes of Health
  3. A new multiphase polymeric material for cushion-bearing orthopedic implants

    Amount: $151,115.00

    DESCRIPTION (provided by applicant): Myelosuppression continues to represent the major dose-limiting toxicity of cancer chemotherapy, resulting in considerable morbidity and mortality along with frequ ...

    SBIRPhase I2013Department of Health and Human Services National Institutes of Health
  4. Organismal Radioprotection Through Pharmacological Quiescence

    Amount: $3,000,000.00

    DESCRIPTION (provided by applicant): Syndrome (ARS), including a lethal myelosuppression due to the sensitivity of proliferating hematopoietic stem/progenitor cells (HSPCs) to ionizing radiation (IR). ...

    SBIRPhase II2011Department of Health and Human Services National Institutes of Health
  5. Organismal Radioprotection Through Pharmacological Quiescence

    Amount: $692,326.00

    DESCRIPTION (provided by applicant): Hematologic toxicity is a principal cause of morbidity and mortality after exposure to ionizing radiation (IR). G-Zero Therapeutics, with operations in the Res ...

    SBIRPhase I2009Department of Health and Human Services National Institutes of Health
US Flag An Official Website of the United States Government